{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T21:12:08Z","timestamp":1793394728604,"version":"4.5.0"},"reference-count":18,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Childhood Ewing sarcoma (ES) \u2013 both osseous and extraosseous \u2013 has good outcomes with aggressive treatment that includes chemotherapy, surgery, and radiation therapy (RT). In this paper, we report our experience on the survival and prognostic factors of ES.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods:<\/jats:title>\n                    <jats:p>Seventy-four newly diagnosed patients with ES, less than 14 years of age, registered in Pediatric Oncology Department of our center, over a period of 5 years, from July 1, 2010 to June 30, 2015, were included.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Mean age at presentation was 8.93 years. Primary osseous sites were the extremity (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      = 30), pelvis (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      = 10), chest wall (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      = 9), spine (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      = 7), and skull (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      = 5), and the extraosseous primary site was involved in 17.6% (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      = 13). Metastatic disease was present in 17 patients (23%). Also, 52 patients received three-weekly vincristine\/doxorubicin\/cyclophosphamide (VDC)\/ifosfamide\/etoposide (IE) and 21 patients received only VDC. There was no treatment-related mortality. Local control modalities were surgery alone (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      = 12), definitive RT (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      = 33), surgery and RT (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      = 20), palliative RT (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      = 4), or none (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      = 4). At a median duration of follow-up of 64 months, the 5-year event-free survival (EFS) for the entire cohort was 50.4% (60.6% for localized and 17.6% for metastatic) and the 5-year overall survival (OS) was 54.6% (64.2% for localized and 23.5% for metastatic). Among the prognostic factors analyzed (age, gender, lactate dehydrogenase [LDH] levels, site, and metastases), presence of metastases was the only factor significantly associated with poorer EFS and OS.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Localized ES has a favorable outcome even in resource-limited settings, and treatment intensification by interval-compressed chemotherapy may improve the outcomes further. Presence of metastasis at presentation confers a poor outcome.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/ijc.ijc_1149_21","type":"journal-article","created":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T00:00:23Z","timestamp":1750982423000},"page":"57-63","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Survival and prognostic factors of childhood Ewing sarcoma \u2013 Experience from a cancer center in South India"],"prefix":"10.4103","volume":"62","author":[{"given":"Binitha","family":"Rajeswari","sequence":"first","affiliation":[{"name":"Department of Pediatric Oncology, Regional Cancer Centre, Thiruvananthapuram, Kerala, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"VR","family":"Prasanth","sequence":"additional","affiliation":[{"name":"Department of Pediatric Oncology, Regional Cancer Centre, Thiruvananthapuram, Kerala, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priyakumari","family":"Thankamony","sequence":"additional","affiliation":[{"name":"Department of Pediatric Oncology, Regional Cancer Centre, Thiruvananthapuram, Kerala, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manjusha","family":"Nair","sequence":"additional","affiliation":[{"name":"Department of Pediatric Oncology, Regional Cancer Centre, Thiruvananthapuram, Kerala, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guruprasad Chellappan","family":"Sojamani","sequence":"additional","affiliation":[{"name":"Department of Pediatric Oncology, Regional Cancer Centre, Thiruvananthapuram, Kerala, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arun","family":"Sankar","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Regional Cancer Centre, Thiruvananthapuram, Kerala, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhaskar Subin","family":"Sugath","sequence":"additional","affiliation":[{"name":"Department of Honorary Consultant Orthopedics, Regional Cancer Centre, Thiruvananthapuram, Kerala, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K M Jagathnath","family":"Krishna","sequence":"additional","affiliation":[{"name":"Department of Division of Cancer Epidemiology and Biostatistics, Regional Cancer Centre, Thiruvananthapuram, Kerala, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Kusumakumary","sequence":"additional","affiliation":[{"name":"Department of Pediatric Oncology, Regional Cancer Centre, Thiruvananthapuram, Kerala, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K","family":"Jayasree","sequence":"additional","affiliation":[{"name":"Department of Pathology, Regional Cancer Centre, Thiruvananthapuram, Kerala, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,5,16]]},"reference":[{"key":"R1-20250627","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1056\/NEJMoa020890","article-title":"Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone","volume":"348","author":"Grier","year":"2003","journal-title":"N Engl J Med"},{"key":"R2-20250627","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1002\/jso.23861","article-title":"Developing a prognostic model for localized Ewing sarcoma family of tumors: A single institutional experience of 224 cases treated with uniform chemotherapy protocol","volume":"111","author":"Biswas","year":"2015","journal-title":"J Surg Oncol"},{"key":"R3-20250627","doi-asserted-by":"crossref","first-page":"841","DOI":"10.2106\/JBJS.M.00411","article-title":"Outcomes and prognostic factors for Ewing-family tumors of the extremities","volume":"96","author":"Biswas","year":"2014","journal-title":"J Bone Joint Surg Am"},{"key":"R4-20250627","doi-asserted-by":"crossref","first-page":"37","DOI":"10.4103\/ijc.IJC_481_17","article-title":"Analysis of bone and soft-tissue sarcomas registered during the year 2012 at Tata memorial hospital, Mumbai, with clinical outcomes","volume":"55","author":"Bajpai","year":"2018","journal-title":"Indian J Cancer"},{"key":"R5-20250627","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1093\/jnci\/djq278","article-title":"Long-term survivors of childhood Ewing sarcoma: Report from the childhood cancer survivor study","volume":"102","author":"Ginsberg","year":"2010","journal-title":"J Natl Cancer Inst"},{"key":"R6-20250627","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1002\/pbc.25837","article-title":"Pilot study of adding vincristine, topotecan, and cyclophosphamide to interval-compressed chemotherapy in newly diagnosed patients with localized Ewing sarcoma: A report from the children's oncology group","volume":"63","author":"Mascarenhas","year":"2016","journal-title":"Pediatr Blood Cancer"},{"key":"R7-20250627","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1002\/cncr.29065","article-title":"Comparative evaluation of local control strategies in localized Ewing sarcoma of bone: A report from the children's oncology group","volume":"121","author":"DuBois","year":"2015","journal-title":"Cancer"},{"key":"R8-20250627","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.ejca.2016.03.075","article-title":"Can postoperative radiotherapy be omitted in localised standard-risk Ewing sarcoma?An observational study of the Euro-E. W. I. N. G group","volume":"61","author":"Foulon","year":"2016","journal-title":"Eur J Cancer"},{"key":"R9-20250627","doi-asserted-by":"crossref","first-page":"e27011","DOI":"10.1002\/pbc.27011","article-title":"Recurrence of Ewing sarcoma: Is detection by imaging follow-up protocol associated with survival advantage?","volume":"65","author":"Heinemann","year":"2018","journal-title":"Pediatr Blood Cancer"},{"key":"R10-20250627","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1002\/pbc.25095","article-title":"Evaluation of outcome and prognostic factors in extraosseous Ewing sarcoma","volume":"61","author":"Biswas","year":"2014","journal-title":"Pediatr Blood Cancer"},{"key":"R11-20250627","doi-asserted-by":"crossref","first-page":"4148","DOI":"10.1200\/JCO.2011.41.5703","article-title":"Randomized controlled trial of interval-compressed chemotherapy for the treatment of localized Ewing sarcoma: A report from the children's oncology group","volume":"30","author":"Womer","year":"2012","journal-title":"J Clin Oncol"},{"key":"R12-20250627","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1016\/j.clon.2014.05.006","article-title":"Hypoalbuminaemia is an independent predictor of poor outcome in metastatic Ewing's sarcoma family of tumours: A single institutional experience of 150 cases treated with uniform chemotherapy protocol","volume":"26","author":"Biswas","year":"2014","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"R13-20250627","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1002\/(SICI)1097-0142(19990801)86:3<421::AID-CNCR10>3.0.CO;2-O","article-title":"Italian cooperative study for the treatment of children and young adults with localized Ewing sarcoma of bone: A preliminary report of 6 years of experience","volume":"86","author":"Rosito","year":"1999","journal-title":"Cancer"},{"key":"R14-20250627","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1002\/cncr.22821","article-title":"Analysis of prognostic factors in Ewing sarcoma family of tumors: Review of St. Jude children's research hospital studies","volume":"110","author":"Rodriguez-Galindo","year":"2007","journal-title":"Cancer"},{"key":"R15-20250627","doi-asserted-by":"crossref","first-page":"3816","DOI":"10.1245\/s10434-012-2458-4","article-title":"Analysis of prognostic factors in extraosseous Ewing sarcoma family of tumors: Review of St. Jude children's research hospital experience","volume":"19","author":"Orr","year":"2012","journal-title":"Ann Surg Oncol"},{"key":"R16-20250627","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1200\/JCO.2001.19.6.1818","article-title":"Localized Ewing tumor of bone: Final results of the cooperative Ewing's sarcoma study CESS 86","volume":"19","author":"Paulussen","year":"2001","journal-title":"J Clin Oncol"},{"key":"R17-20250627","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1016\/j.ejca.2012.03.017","article-title":"Risk adapted chemotherapy for localised Ewing's sarcoma of bone: The French EW93 study","volume":"48","author":"Gaspar","year":"2012","journal-title":"Eur J Cancer"},{"key":"R18-20250627","doi-asserted-by":"crossref","first-page":"8828","DOI":"10.1200\/JCO.2005.01.7079","article-title":"[18F] Fluorodeoxyglucose positron emission tomography predicts outcome for Ewing sarcoma family of tumors","volume":"23","author":"Hawkins","year":"2005","journal-title":"J Clin Oncol"}],"container-title":["Indian Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/ijc.ijc_1149_21","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:44:30Z","timestamp":1787067870000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ijc.ijc_1149_21"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":18,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.4103\/ijc.ijc_1149_21","relation":{},"ISSN":["0019-509X","1998-4774"],"issn-type":[{"value":"0019-509X","type":"print"},{"value":"1998-4774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"2021-09-24","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-06-16","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}